Insys Therapeutics, Inc.

Track this case

Case Number:

1:19-bk-11292

Court:

Delaware

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

August 22, 2019
Insys Ch. 11 Sales For Two Drug Lines Approved In Del.

Bankrupt pharmaceutical company Insys Therapeutics received court approval Thursday in Delaware for a pair of asset sales that will transfer certain drug lines in deals worth more than $29 million.
August 20, 2019
Insys Creditors Want More Guarantees In Severance Plan

Insys Therapeutics Inc.'s unsecured creditors want assurance that employees "involved or complicit" in criminal conduct will not receive severance pay as part of the pharmaceutical company's Chapter 11, they told a Delaware bankruptcy court Tuesday.
August 12, 2019
Feds Say Insys Needs Consent To Sell Gov't Deals In Ch. 11

The federal government filed an objection in Delaware bankruptcy court Friday to disgraced drugmaker Insys Therapeutics' proposed assignment of Medicaid, Medicare and military contracts in its Chapter 11 sale, saying the contracts can't be sold without government consent.
August 09, 2019
Insys Plans $29M CBD And Naloxone Sale In Ch. 11

Embattled and bankrupt drugmaker Insys Therapeutics Inc. has entered into agreements to sell the company's naloxone spray and cannabis-based products to a pair of companies for a total of $29 million, according to a regulatory filing late Thursday that made no mention of the company's infamous opioid spray.
August 08, 2019
Hospitals Want Claim In Insys Ch. 11 That Could Hit $102B

Four hospitals hard hit by the opioid epidemic urged a Delaware bankruptcy judge Wednesday to allow filing of a class damages claim for all hospitals nationwide in Insys Therapeutics Inc.'s Chapter 11 case, with overall damages to the class estimated at more than $102 billion.
July 24, 2019
Cities, Counties Lose Bid For Committee In Insys Ch. 11 Case

Two cities and two counties lost their bid for a creditors committee of public entities in opioid maker Insys Therapeutics' Chapter 11 case when a Delaware bankruptcy judge ruled Wednesday they hadn't shown the new body was necessary.
July 23, 2019
Insys Pulls Support For Novel Gov't Entities Committee

Bankrupt drugmaker Insys Therapeutics Inc. on Tuesday pulled its support for the formation of a public entities committee in its Chapter 11 after plaintiffs in massive opioid multidistrict litigation blasted the proposed action as being virtually powerless.
July 22, 2019
Trustee, MDL Group, Maryland AG Blast Insys Ch. 11 Proposal

The federal bankruptcy watchdog, Maryland's attorney general and counsel for plaintiffs in massive opioid multidistrict litigation are all ripping a proposal to appoint a "public entities committee" in drugmaker Insys Therapeutics Inc.'s Chapter 11 case, arguing it either goes too far or not far enough.
July 15, 2019
Insys Proposes Novel Gov't Committee Deal In Ch. 11 Case

Bankrupt drugmaker Insys Therapeutics Inc. reached a deal with a group of government entities seeking representation in its Chapter 11 case Monday by proposing the formation of a limited-purpose committee of local agencies that will be able to participate in plan negotiations.
July 02, 2019
Insys Reaches Ch. 11 Deal To Pause State Opioid Suits

A Delaware bankruptcy judge on Tuesday gave his nod to a deal that Insys Therapeutics Inc. has brokered with a handful of state attorneys general to pause opioid litigation as the company moves forward with plans for its Chapter 11 sale.